Portage Biotech doses first patient in Phase 1a trial of PORT-6

Portage Biotech has dosed the first patient in its Phase 1a trial, ADPORT-601. The trial is evaluating Portage’s adenosine 2A receptor antagonist candidate, PORT-6, in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer. ADPORT-601 is an adaptive Phase 1a/1b trial evaluating the safety and efficacy of PORT-6. The trial also plans to evaluate Portage’s adenosine 2B receptor antagonist and integrate proprietary biomarkers to select patients with high A2A and A2B expression. This approach is expected to allow for customization of treatment for any given tumor type to identify patients that are more likely to respond and have potential to benefit most from treatment.